Brief report
Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe

https://doi.org/10.1016/j.amjcard.2003.11.060Get rights and content

Abstract

This small retrospective study confirms the hypothesis that patients who are hyporesponders to statin therapy are hyper-responders to ezetimibe therapy and may help identify a patient population in whom ezetimibe would be particularly effective in lowering low-density lipoprotein cholesterol.

References (6)

There are more references available in the full text version of this article.

Cited by (27)

  • Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk?

    2021, Atherosclerosis
    Citation Excerpt :

    Evidence from metabolic studies for the existence of such metabotypes, who are respectively less and more sensitive to dietary cholesterol, may underlie the phenomenon of hypo and hyper-responsiveness of serum LDL-C to dietary cholesterol, which may, in part, be an inherited trait [46]. The relatively greater efficacy of LDL-lowering drugs that either inhibit cholesterol synthesis or block absorption in the gut (e.g. statins and ezetimibe) in synthesisers or absorbers of cholesterol, respectively, provides further evidence for the existence of these discrete metabotypes [47,48]. The additive and even synergistic effects of dietary SFA and dietary cholesterol on serum LDL-C, reflect the fact that these dietary lipids share common determinants of cholesterol homeostasis.

  • Combined treatment: Regimens, indications and safety profile

    2013, Clinica e Investigacion en Arteriosclerosis
  • Ezetimibe

    2005, FMC Formacion Medica Continuada en Atencion Primaria
View all citing articles on Scopus
View full text